Clinical Trials
Recent cancer clinical trials sourced from ClinicalTrials.gov. Trials are listed for informational purposes only. Always consult your healthcare provider before making decisions about clinical trial participation.
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Nemtabrutinib, Ibrutinib, Acalabrutinib
NCT06136559 - View on ClinicalTrials.gov →Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Interventions: Rapcabtagene autoleucel single agent, Ibrutinib
NCT03960840 - View on ClinicalTrials.gov →Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Conditions: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Interventions: Nemtabrutinib
NCT04728893 - View on ClinicalTrials.gov →Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
NCT05727904 - View on ClinicalTrials.gov →Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis, Pharmacological Study
NCT02627443 - View on ClinicalTrials.gov →S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Conditions: MTAP-deleted Solid Tumors
Interventions: S095035, TNG462
NCT06188702 - View on ClinicalTrials.gov →PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PTM-101
NCT06673017 - View on ClinicalTrials.gov →LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Conditions: Colorectal Cancer, Liver Metastasis, LDRT
Interventions: Low Dose Radiotherapy, Short course Radiotherapy, XELOX, Tislelizumab
NCT06848465 - View on ClinicalTrials.gov →Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions: Questionnaire Administration, Biospecimen Collection
NCT05334069 - View on ClinicalTrials.gov →Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
NCT05946213 - View on ClinicalTrials.gov →Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: FPI-2265
NCT05219500 - View on ClinicalTrials.gov →Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
NCT04513717 - View on ClinicalTrials.gov →Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Conditions: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Neoplasms, Male, Urogenital Neoplasms, Urogenital Cancers, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Neoplasms, Neoplasms by Site, Prostate Cancer
Interventions: Pocenbrodib, Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
NCT06785636 - View on ClinicalTrials.gov →A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → MutationsA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed
NCT05048797 - View on ClinicalTrials.gov →Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →
Conditions: Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions: Carboplatin, Paclitaxel, Pevonedistat
NCT03965689 - View on ClinicalTrials.gov →Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
NCT05624996 - View on ClinicalTrials.gov →Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Conditions: HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Endoxifen Hydrochloride, Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis, Pharmacological Study, Questionnaire Administration
NCT01327781 - View on ClinicalTrials.gov →A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-Negative Advanced Breast Cancer
Conditions: Breast Cancer
Interventions: Inavolisib, Placebo, CDK4/6i, Letrozole
NCT06790693 - View on ClinicalTrials.gov →A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC), Hormone Receptor-Positive Breast Cancer, HER2 + Breast Cancer
Interventions: Two Component Product CLBR001 + ABBV-461
NCT06878248 - View on ClinicalTrials.gov →Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment
NCT06500481 - View on ClinicalTrials.gov →Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation
Conditions: Cervical Cancers, Breast Cancer, Oral Cancer
Interventions: Lived experience video campaign
NCT06874985 - View on ClinicalTrials.gov →A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-) Breast Cancer
Conditions: Breast Cancer
Interventions: GDC-0587, Giredestrant, Omeprazole
NCT07214662 - View on ClinicalTrials.gov →MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12Cm NSCLC (MK-1084-013)
Conditions: Non-small Cell Lung Cancer
Interventions: MK-1084, MK-3475A, Placebo
NCT07431827 - View on ClinicalTrials.gov →Testing the Addition of AZD6738 (Ceralasertib) to ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
NCT06732401 - View on ClinicalTrials.gov →Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Cetuximab, Encorafenib, Nivolumab
NCT05308446 - View on ClinicalTrials.gov →Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
NCT04345913 - View on ClinicalTrials.gov →M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
Interventions: Berzosertib, Biopsy Specimen, Biospecimen Collection, Computed Tomography, Irinotecan Hydrochloride
NCT02595931 - View on ClinicalTrials.gov →Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions: Cisplatin, Methoxyamine, Pemetrexed Disodium
NCT02535312 - View on ClinicalTrials.gov →Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Biospecimen Collection, Bone Marrow Aspiration, Buccal Swab, Iadademstat, Venetoclax
NCT06514261 - View on ClinicalTrials.gov →A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Interventions: Azacitidine, ASTX030 (cedazuridine + azacitidine), Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Venetoclax
NCT04256317 - View on ClinicalTrials.gov →Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
Interventions: Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
NCT05372640 - View on ClinicalTrials.gov →Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions: Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis, Quality-of-Life Assessment, Rituximab
NCT01886872 - View on ClinicalTrials.gov →Testing a New ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Navtemadlin, Venetoclax
NCT03041688 - View on ClinicalTrials.gov →Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
Conditions: Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions: Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
NCT03348631 - View on ClinicalTrials.gov →A Study of Tarlatamab for People With Prostate Cancer
Conditions: Metastatic Prostate Cancer
Interventions: Tarlatamab
NCT07111507 - View on ClinicalTrials.gov →Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-Negative Breast Cancer
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
NCT02453620 - View on ClinicalTrials.gov →Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
NCT06317649 - View on ClinicalTrials.gov →Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Conditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
NCT05111574 - View on ClinicalTrials.gov →Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Laboratory BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Analysis, Pharmacological Study, Riluzole, Sorafenib Tosylate
NCT01303341 - View on ClinicalTrials.gov →Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Conditions: Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
NCT05554367 - View on ClinicalTrials.gov →